**Core tip:** This retrospective study evaluated the image quality of free-breathing diffusion-weighted imaging (FB-DWI) of the liver and its diagnostic performance for hepatocellular carcinoma compared with respiratory-triggered DWI. The free-breathing technique is widely believed to be inappropriate for body DWI because motion artifact causes decreased image quality. However, after a modification of imaging parameters, FB-DWI showed better image quality without significantly reducing the signal-to-noise ratio of the normal liver parenchyma and the lesion-to-nonlesion contrast-to-noise ratio compared to respiratory-triggering-DWI. As a result, the improvement of the image quality of FB-DWI contributed to an increased rate of detection of hepatocellular carcinoma.

INTRODUCTION
============

Diffusion-weighted imaging (DWI) has been widely adopted as a magnetic resonance imaging (MRI) method in clinical practice\[[@B1],[@B2]\]. DWI can be used for the detection and characterization of malignant and nonmalignant lesions\[[@B3]-[@B5]\]. Liver DWI has been applied to quantify the degrees of chronic liver disease and fibrosis, and to detect and characterize liver lesions\[[@B2],[@B6]-[@B9]\]. DWI can provide additional information that can be used to differentiate malignant liver lesions from benign liver lesions and to estimate the histological grade of hepatocellular carcinomas (HCCs)\[[@B6],[@B7],[@B10]\]. The combination of DWI and dynamic contrast-enhanced (DCE)-MRI has shown higher diagnostic performance compared to DWI or DCE-MRI alone\[[@B11]-[@B13]\]. Although DWI has an essential role to play in the assessment of HCCs on liver MRI, its sensitivity for detecting HCCs is thought to be low compared to that of DCE-MRI\[[@B2],[@B14]\].

DWI suffers from image distortion and/or chemical shift artifacts related to the echo planar imaging (EPI) technique and to motion and susceptibility artifacts\[[@B15]-[@B17]\]. With the goal of overcoming these issues, a previous study investigated MR parameter settings to obtain high spatial resolution and less artifacts without losing a significant level of the signal-to-noise ratio on liver MRI\[[@B18]\]. With this method, DWI with MR parameter settings provides improved image quality and detections of malignant liver tumors such as HCCs and metastatic liver tumors\[[@B18]\]. Here we hypothesized that DWI with modified MR parameter settings for the improvement of image quality might result in further improvement in the detectability of HCCs.

The purpose of this retrospective study was to evaluate the image quality and the detectability of HCCs in patients with chronic liver disease on DWI with modified MR parameter settings.

MATERIALS AND METHODS
=====================

Subjects
--------

This study was approved by the Institutional Review Board of our institute. The requirement for written informed consent was waived due to the retrospective nature of the study. From November 2010 to September 2011, 468 consecutive patients who underwent liver MRI at our institute were enrolled. The inclusion criteria were: (1) patients who were admitted to the Department of Surgery and were suspected to have HCCs due to chronic liver disease; (2) patients who underwent gadoxetic acid-enhanced MRI (Gd-EOB-MRI) on the same MR scanners; and (3) patients who underwent treatments such as surgical resection, transcatheter arterial infusion chemotherapy (TAI) or transcatheter arterial chemoembolization (TACE). The exclusion criteria were: (1) patients with other malignant liver tumors, such as cholangiocellular carcinoma (ICC) and metastatic liver tumor; and (2) patients in whom follow-up computed tomography (CT) and/or MRI were not performed. Finally, 51 patients (age range: 26-82; mean: 63.8 years; male/female ratio: 33/18; Child-Pugh grades: A = 31, B = 16 and C = 4) were enrolled.

Imaging protocol
----------------

**MR protocol:** MR examinations were performed on a clinical whole-body 3.0 Tesla MR system (Achieva 3.0 T TX; Philips Healthcare, Best, the Netherlands) using a 32-channel cardiac phased-array coil. For the comparison of imaging modalities, each patient was scanned with two different types of DWI. One type was DWI with modified MR parameter settings for the improvement of images referring to the literature\[[@B18]\]; we called this type of DWI "free-breathing (FB)-DWI" in this study because the FB technique was applied. The other type was DWI without modified MR parameter settings using a navigator-echo-based, real-time respiratory-gating and respiratory-triggering technique which we refer to as RT-DWI in this study. A navigator-echo-based technique was not applied for respiratory-triggering (RT)-DWI.

The details of the MR parameters of the two DWI methods are summarized in Table [1](#T1){ref-type="table"}. An apparent diffusion coefficient (ADC) map was developed for each DW image, by referring to the signal intensity decay on the DW image with *b*-values of 0, 500 and 1000 s/mm^2^.

###### 

Details of magnetic resonance parameters

  **Imaging technique**        **FB-DWI**                              **RT-DWI**
  ---------------------------- --------------------------------------- -------------------------------------------
  SENSE factor                 2                                       2
  TR/TE (ms)                   6250/56                                 1877/55
  Flip angle (degree)          90°                                     90°
  Field of view (mm^2^)        380 × 299                               380 × 299
  Matrix (frequency × phase)   112 × 176                               112 × 68
  Slice thickness (mm)         7                                       7
  Slice gap (mm)               1                                       1
  No. of slice                 25                                      25
  No. of excitations           2                                       2
  *b*-value (s/mm^2^)          0.500 and 1.000                         0.500 and 1.000
  Respiratory compensation     Free-breathing without navigator echo   Respiratory-triggered with navigator echo
  Fat-suppression              SPAIR                                   SPIR
  SPAIR delay (ms)             100                                     
  SPAIR TR (ms)                250                                     
  Frequency offset (Hz)        250                                     180
  EPI factor                   75                                      25
  Band width (Hz/pixel)        4050.4                                  4438.5
  Scan time (min:s)            3:32                                    3:20[1](#T1FN1){ref-type="table-fn"}

The mean scan time of RT-DWI, because these values vary depending on the subjects' respiration condition. FB-DWI: Diffusion-weighted imaging with modified MR parameter settings for image improvement by referring to the literature\[[@B18]\]; RT-DWI: Respiratory-triggered diffusion-weighted imaging without modified MR parameter settings for the image improvement; EPI: Echo planar imaging; TR: Repetition time; TE: Echo time; SPAIR: Spectral attenuation with inversion recovery; SPIR: Spectral presaturation with inversion recovery; SPAIR delay: Inversion time from exposure of SPAIR pulse; SPAIR TR: TR between SPAIR pulses during the scan; Frequency offset: Bandwidth from the frequency of fat tissue; EPI factor: The number of k-space profiles collected per excitation.

Other imaging sequences included an axial T2-weighted single-shot turbo spin echo, axial dual-echo T1-weighted fast field echo, and a gadoxetic acid-enhanced dynamic study. For the gadoxetic acid-enhanced dynamic study, a multiphase dynamic study including arterial, portal, late and hepatobiliary phases was performed using axial enhanced T1 high-resolution isotropic volume excitation (eTHRIVE). First, pre-contrast images were scanned. Gadoxetic acid (Primovist; Bayer, Osaka, Japan) at 0.1 mL/kg was injected through the antecubital vein for 5 s at a variable injection rate using a power injector, followed by a bolus administration of 20 mL of saline at the same injection rate. The timing of the arterial dominant phase was determined with a test injection of 0.5 mL of gadoxetic acid. The scanning of the portal, late and hepatobiliary phases began at the arterial phase +30 s, 180 s and 20 min after the injection of the contrast agent, respectively.

**CT protocol:** On the follow-up CT examination, the scanning was performed before and after 100 mL of iodinated contrast medium (Iopamiron 370: Bayer Schering Pharma, Osaka, Japan; or Omnipaque 350: Daiichi-Sankyo, Tokyo) was administered, using a 64-MDCT scanner (Aquilion 64, Toshiba Medical, Tokyo). The contrast was intravenously administered at a rate of 3 mL/s. Contrast-enhanced images were obtained during the arterial phase (43 s after the initiation of the injection), the portal venous phase (70 s), and the delayed phase (240 s). The imaging acquisition parameters were as follows: Voltage, 120 kV; electric current, automatic; collimation, 0.5 mm; image reconstruction thickness, 5 mm; and helical pitch, 53.

Image quality assessment
------------------------

Qualitatively, the sharpness of the liver contour, the image noise and the chemical shift artifacts on FB-DWI and RT-DWI with *b*-values of 1000 s/mm^2^ were independently evaluated by three radiologists (Daisuke Kakihara, Yasuhiro Ushijima, and Nobuhiro Fujita, with 17, 17 and 12 years of experience in interpreting liver MRI, respectively) who were blinded to the imaging information and clinical data, using 4-point scoring. The details of the 4-point scoring are shown in Table [2](#T2){ref-type="table"}. Quantitatively, the SNRs of the liver parenchyma and the lesion-to-nonlesion CNRs between the liver parenchyma and HCCs were calculated after drawing polygonal regions of interest (ROIs) on each DWI with a b-factor of 1000 s/mm^2^; this procedure was performed by one radiologist using a commercially available PACS workstation (SYNAPSE; Fujifilm Medical, Tokyo). The SNRs and CNRs were calculated using the following equations, as described in detail elsewhere\[[@B19],[@B20]\]:

###### 

Image quality scores of sharpness of the liver contour, distortion and chemical shift artifacts

  **Score**   **Sharpness of the liver contour**       **Distortion and chemical shift artifacts**
  ----------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  1           Unclear liver contour                    Severe distortion or artifacts compromise the diagnostic capability of DWI in the whole liver
  2           The liver contour is partially unclear   Distortion or artifacts are moderate, and they compromise the diagnostic capability of DWI in 50% or more of the liver
  3           The liver contour is mostly clear        Distortion or artifacts are mild, and they compromise the diagnostic capability of DWI in less than 50% of the liver
  4           The entire liver contour is clear        No distortion or artifacts; the diagnostic capability of DWI is not compromised

DWI: Diffusion-weighted imaging.

SNR of the liver parenchyma = SI~liver~/SD~liver~, Lesion to nonlesion CNR = \|SI~liver~ − SI~tumor~\|/SD~liver~

Where SI~liver~ is the signal intensity of the liver parenchyma, SI~tumor~ the signal intensity of the tumor, and SD~liver~ the standard deviation of the SI of the liver parenchyma. The SD of the liver parenchyma was taken as the estimated local noise for the calculation. In parallel imaging, noise is not distributed homogeneously throughout the image, and thus it is better to estimate noise in close proximity to the site of SI measurement\[[@B21]\]. The SNR cannot be calculated as a characteristic of the entire image but rather is calculated as a local property that characterizes the signal quality with respect to local noise levels\[[@B21]\].

Three ROIs were made as large as possible on the normal liver parenchyma to avoid major vessels, tumors, and artifacts for each patient. The same ROIs were duplicated on each DW image. The range and averaged areas of ROIs of the normal liver parenchyma were 102.1-1414.0 mm^2^ and 385.4 mm^2^, and the corresponding values for the hepatic lesions were 146.7-1237.4 mm^2^ and 502.7 mm^2^. The measurements of the SNR of normal liver parenchyma and a lesion-to-nonlesion CNR were repeated three times for each subject. The same ROIs were duplicated at the same slice and position for the two DWI methods.

Confirmation of HCC
-------------------

A final total of 105 HCCs (size range: 5-140 mm; mean: 17.1 mm; location, left lobe/right lobe: 52/53) was used for the assessment of the detectability of HCCs by the two different types of DWI. The number and location of HCCs were determined by one coordinator (Yukihisa Takayama, with 15 years of experience in interpreting liver MRI) who was a coordinator of this study and had knowledge of the clinical data of each patient. In the 38 patients who underwent surgery, 38 HCCs were identified using pathological reports after surgical resection. Of the other 67 HCCs in the 13 patients who underwent TAI or TACE, the HCCs were clinically defined using the enhancement in the early phase and hypointensity in the hepatobiliary phase of Gd-EOB-MRI and the nodular accumulation of emulsion of iodized oil (Lipiodol Ultrafluid; Terumo, Tokyo) on follow-up CT performed 2 wk after the TAI or TACE\[[@B22]-[@B24]\].

The 3-mo follow-up Gd-EOB-MRI or DCE-CT confirmed the absence of HCCs in other liver parenchyma. The treated HCCs and hepatic hemangiomas were diagnosed based on the lack of early enhancement on Gd-EOB-MRI and DCE-CT and high signal intensity on T2-weighted imaging at an least 6-mo follow-up Gd-EOB-MRI or DCE-CT\[[@B24]-[@B26]\]. Liver tumors other than hemangiomas were not identified in 51 patients.

Detectability of HCC
--------------------

The detectability of HCC by each type of DWI was analyzed by three radiologists (Daisuke Kakihara, Yasuhiro Ushijima, and Nobuhiro Fujita, with 17, 17 and 12 years of experience in interpreting liver MRI, respectively) who independently interpreted the sets of DWI with *b*-values of 0, 500 and 1000 s/mm^2^ and the ADC map at a 1-mo interval in random order. They were blinded to the clinical data and other imaging results such as those obtained by T1- and T2-weighted imaging, Gd-EOB-MRI, and DCE-CT.

On each type of DWI, HCC was diagnosed as a lesion showing mild-to-moderate hyperintensity compared to the liver parenchyma on DW images at a *b*-value of 0 s/mm^2^ and restricted diffusion (*i.e*., the lesion remained hyperintense) at a *b*-value of 500 and/or 1000 s/mm^2^, with an ADC value visually lower or equal to that of the surrounding liver parenchyma. Liver hemangiomas were diagnosed by referring to the hyperintensity on DWI with a *b*-value of 0 s/mm^2^ and an ADC value visually higher than that of the surrounding liver parenchyma. Each observer recorded the location of each HCC by placing an arrow on the image. The detectability of HCC was calculated on a tumor-by-tumor basis, and the detectability provided by the two types of DWI were compared. If liver hemangiomas were interpreted by each observer as HCC, those lesions were considered false-positives and were excluded from the assessment of detectability by the coordinator. In addition, the relationship between detectability and the sizes of the HCCs was analyzed.

Statistical analysis
--------------------

Image quality scores of the sharpness of the liver contour, the distortion, and the chemical shift artifacts between FB-DWI and RT-DWI were compared with the Wilcoxon signed-rank test. The SNRs of normal liver parenchyma and lesion-to-nonlesion CNRs between the two types of DWI were compared with a paired *t*-test. The detectability provided by the two DWI methods was compared using McNemar's test. A *P*-value \< 0.05 was considered to indicate a significant difference for each analysis. Statistical analyses were performed using IBM SPSS statistics 18.0 software (IBM Japan, Tokyo). The statistical methods of this study were reviewed by Akihiro Nishie from the Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University and Junji Kishimoto from the Center for Clinical and Translational Research, Kyushu University.

RESULTS
=======

Image quality assessments
-------------------------

The results of the qualitative assessment by the three observers are shown in Table [3](#T3){ref-type="table"}. For all three observers, the average image quality scores of the sharpness of the liver contour, the distortion, and the chemical shift artifacts of FB-DWI were significantly higher than those of RT-DWI (*P* \< 0.05). There were no significant differences between FB-DWI and RT-DWI in the average or SDs of the SNR of the normal liver parenchyma (FB-DWI, 11.0 ± 4.8; RT-DWI, 11.0 ± 5.0) or the lesion-to-nonlesion CNR (FB-DWI, 21.4 ± 17.7; RT-DWI, 20.1 ± 15.1). Three representative cases are shown in Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}.

![A 36-year-old male. The HCC in segment 8 of the liver showing hyperintensity on FB-DWI (A) is more clearly described than on RT-DWI (B). The ADC values of HCC were 1.02 × 10^−3^ mm^2^/s on the ADC map of FB-DWI (C) and 1.16 × 10^-3^ mm^2^/s on the ADC map of RT-DWI (D). HCC: Hepatocellular carcinoma; FB-DWI: Free-breathing diffusion-weighted imaging; RT-DWI: Respiratory-triggering diffusion-weighted imaging; ADC: Apparent diffusion coefficient.](WJH-9-657-g001){#F1}

![A 78-year-old female. The HCC in segment 5 of the liver was detected by FB-DWI (A), whereas on RT-DWI, it was concealed by a chemical shift artifact (B). HCC: Hepatocellular carcinoma; FB-DWI: Free-breathing diffusion-weighted imaging; RT-DWI: Respiratory-triggering diffusion-weighted imaging.](WJH-9-657-g002){#F2}

###### 

Results of qualitative assessment of the free-breathing diffusion-weighted imaging and respiratory-triggering-diffusion-weighted imaging results

               **Sharpness of the liver contour**   **Distortion**                                **Chemical shift artifacts**                                                               
  ------------ ------------------------------------ --------------------------------------------- ------------------------------ --------------------------------------------- ------------- ---------------------------------------------
  Observer 1   3.08 ± 0.81                          2.33 ± 0.65[a](#T3FN1){ref-type="table-fn"}   2.94 ± 0.50                    2.81 ± 0.56[a](#T3FN1){ref-type="table-fn"}   3.38 ± 0.60   2.92 ± 0.59[a](#T3FN1){ref-type="table-fn"}
  Observer 2   2.98 ± 0.73                          2.37 ± 0.74[a](#T3FN1){ref-type="table-fn"}   2.71 ± 0.70                    2.25 ± 0.74[a](#T3FN1){ref-type="table-fn"}   3.15 ± 1.07   2.21 ± 0.85[a](#T3FN1){ref-type="table-fn"}
  Observer 3   3.54 ± 0.75                          2.75 ± 0.81[a](#T3FN1){ref-type="table-fn"}   3.27 ± 0.53                    2.96 ± 0.71[a](#T3FN1){ref-type="table-fn"}   3.21 ± 0.85   2.77 ± 1.08[a](#T3FN1){ref-type="table-fn"}

Data are the average ± SD.

*P* \< 0.05 by the Wilcoxon signed-rank test. FB-DWI: Diffusion-weighted imaging with modified MR parameter settings for image improvement by referring to the literature\[[@B18]\]; RT-DWI: Navigator-echo-based, real-time respiratory-gating and respiratory-triggered diffusion-weighted imaging without modified MR parameter settings.

![A 53-year-old female. There was no detectable lesion on FB-DWI (A) but the nodular hyperintensity in segment 7 of the liver was seen on RT-DWI (B). It was diagnosed as a pseudolesion caused by a chemical shift artifact from fat tissue between the liver parenchyma and diaphragm, by referring to precontrast-enhanced imaging (C) and hepatobiliary phase imaging (D) of Gd-EOB-MRI. A follow-up MR examination also showed no progressive lesion (not shown). FB-DWI: Free-breathing diffusion-weighted imaging; RT-DWI: Respiratory-triggering diffusion-weighted imaging; Gd-EOB-MRI: Gadoxetic acid-enhanced magnetic resonance imaging.](WJH-9-657-g003){#F3}

In Figure [1](#F1){ref-type="fig"}, the HCC is more clearly described as hyperintensity on FB-DWI than on RT-DWI. In Figure [2](#F2){ref-type="fig"}, the HCC was detected by FB-DWI, whereas it was concealed by a chemical shift artifact on RT-DWI. A pseudolesion caused by a chemical shift artifact from fat tissue between the liver parenchyma and diaphragm is shown in Figure [3](#F3){ref-type="fig"}.

Detectability of HCC
--------------------

For all three observers, the sensitivity of FB-DWI \[observer (Obs)-1, 43.6%; Obs-2, 53.6%; and Obs-3, 45.0%\] was significantly higher than that of RT-DWI (Obs-1, 29.1%; Obs-2, 43.6%; and Obs-3, 34.5%) (*P* \< 0.05). Regarding the relationship between detectability and the size of the HCCs, the detectability of the two types of DWI was significantly different when the tumor size was 5-22 mm. FB-DWI showed significantly higher detectability of these HCCs (Obs-1, 36.0%; Obs-2, 48.3%; and Obs-3, 33.7%) compared to RT-DWI (Obs-1, 18.0%; Obs-2, 36.0%; and Obs-3, 24.7%) (*P* \< 0.05). There was no significant difference in the detectability of HCCs between the two types of DWI when the tumor size was \> 22 mm.

DISCUSSION
==========

The results of the present study revealed that, compared to RT-DWI, FB-DWI showed better image quality without significantly reducing the SNR of the normal liver parenchyma and the lesion-to-nonlesion CNR. The improvement of the image quality of FB-DWI might contribute to an increased detection rate of HCCs. The free-breathing technique was applied to FB-DWI of liver MRI even though it is widely believed that this technique is inappropriate due to its susceptibility to sensitive motion artifacts, which results in decreased SNRs and CNRs and image blurring\[[@B3],[@B27]\]. However, our present findings demonstrated that FB-DWI had better image quality and equivalent SNRs of the liver parenchyma and lesion-to-nonlesion CNRs compared to RT-DWI.

Other studies have obtained similar results using DWI with a free-breathing technique, such as good image quality, good reproducibility of ADC values of liver tumors, and good diagnostic performance for liver lesions\[[@B28]-[@B31]\]. There are several possible reasons for the good image quality provided by DWI with a free-breathing technique; one is that an increased number of excitations contributes to a reduction in motion artifacts. However, FB-DWI used only two excitations, and thus the results showing good image quality, SNR and CNR cannot be attributed to a multiplicity of excitations.

Another possible reason is the advances in MR technology in recent years (such as statistic and gradient magnetic fields, a 32-channel torso-cardiac phased-array coil, and dual-source parallel radiofrequency excitation and transmission technology) that address problems related to the EPI technique\[[@B9],[@B18],[@B32]\]. In particular, the rapid image acquisition of the EPI sequence allows minimization of the blurring from T2\* signal intensity decay during the gradient-echo train\[[@B9],[@B18],[@B32]\], and it is insensitive to the effects of macroscopic patient motion because of the very fast readout of the complete image data (within approximately 100 ms)\[[@B9]\]. This may account for the good image quality of FB-DWI in the present study.

Homogeneous fat suppression is essential for DWI, to avoid the image degradation caused by chemical shifts when using EPI\[[@B27]\]. For the FB-DWI in the present series, the SPAIR technique was applied because this technique is minimally affected by B1 inhomogeneity and is effective for obtaining homogeneous fat-suppression\[[@B33]\]. Chemical shift artifacts on DWI can be reduced by providing homogeneous fat-suppression as well. Fewer chemical artifacts on DWI are advantageous for the depiction of liver lesions. The present study's findings related to the reduction of chemical shift artifacts occasionally mimicked a hepatic tumor. We thus conclude that FB-DWI will be advantageous for the depiction of HCCs.

In this study, we found that the detectability of HCC by FB-DWI was superior to that by RT-DWI. In fact, the detection of HCC by FB-DWI was equivalent to the reported results using breath-hold or respiratory-triggered techniques (45%-55%)\[[@B2],[@B34],[@B35]\]. That is, FB-DWI provides better spatial resolution, fewer chemical shift artifacts, and a comparable SNR and lesion-to-nonlesion CNR compared to RT-DWI\[[@B18]\]. This improvement in the detectability of HCCs, especially that of small-sized HCCs, is also probably due to the better spatial resolution and fewer chemical shift artifacts of FB-DWI.

The lower detectability of HCCs on DWI alone is a limitation because of the difficulty of differentiating a tumor from surrounding cirrhotic liver due to their similar diffusion properties and ADC values, and to the tumor grades of HCCs\[[@B2],[@B7],[@B14]\]. In contrast, two earlier meta-analyses showed that DWI had high sensitivity (81% and 93%) for detecting HCCs\[[@B13],[@B36]\]. We speculate that the reasons for the difference in the rate of sensitivity between our results and those of the two prior meta-analyses might be related to patient selection bias, the background of liver parenchyma in patients with chronic liver disease (cirrhotic or not), and/or the tumor characteristics (*e.g*., tumor size and malignant grade)\[[@B13],[@B36]\].

Generally, DCE-MRI is the first choice for the evaluation of liver tumors, and DWI is not used alone. However, it is known that the combination of DCE-MRI and DWI improves the detectability and provides additional information to characterize liver lesions\[[@B10]-[@B12],[@B37],[@B38]\]. DWI thus plays an important role in the assessment of liver tumors for patients with contrast-agent contraindications, such as renal failure or a history of adverse reaction to a contrast agent\[[@B38],[@B39]\]. DWI has also been applied for other evaluations of HCCs, such as for assessment of the treatment effects of TACE and molecular target therapy\[[@B40],[@B41]\]. FB-DWI can also contribute to the detection or treatment assessment of HCCs in combination with DCE-MRI.

There are several limitations of this study. First, most of the HCCs examined in this study were confirmed by imaging findings, although some HCCs were confirmed by histological results after surgical resection. Therefore, we did not check the histological subtypes of the HCCs, such as whether they were well-, moderately or poorly differentiated. The more aggressive HCCs (*i.e*., poorly differentiated HCCs) are known to show more water molecule restriction within the tumor compared to the well-differentiated HCCs. In other words, it was difficult to detect well-differentiated HCCs on DWI. In addition, there was a risk to include small ICCs which showed hypervascular tumor like HCCs. However, in this study, we did not focus on the differential diagnosis or characterization of liver tumors. The results of our study were not influenced even if a few ICCs were included in the subjects.

Second, several cases showed severe artifacts at the lateral segment of the liver because of cardiac and respiratory motions. In such cases, the artifacts hampered the visualization of the HCCs. The reduction of motion artifact at the lateral segment of the liver remains a problem to be solved.

In conclusion, FB-DWI provided better image quality and showed higher detectability of HCCs in patients with chronic liver disease compared to RT-DWI, without significantly reducing the SNR of the normal liver parenchyma or the lesion-to-nonlesion CNR. FB-DWI was better at detecting HCCs in patients with chronic liver disease compared to RT-DWI. Free-breathing diffusion-weighted imaging with modified MR parameter settings is advantageous in the diagnosis of HCCs.
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COMMENTS
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Background
----------

Diffusion-weighted imaging (DWI) is widely adopted as a magnetic resonance imaging (MRI) method in clinical practice because it is useful for the detection and characterization of benign and malignant lesions. DWI is also important for liver MRI to evaluate hepatocellular carcinomas (HCCs) in patients with chronic liver disease. Although dynamic contrast-enhanced MRI has shown higher diagnostic performance for HCCs, DWI can be used as a substitute for the detection and characterization of HCCs for patients who have a contraindication for contrast agents. However, liver DWI occasionally suffers from image distortion and/or chemical shift artifacts related to the echo planar imaging technique and to motion and susceptibility artifacts. To overcome these issues, a previous study investigated the ideal MR parameter settings for obtaining high spatial resolution and fewer artifacts without losing a significant portion of the signal-to-noise ratio or contrast-to-noise ratio on liver MRI. Although DWI with modified MR parameter settings for the improvement of image quality might result in further improvement in the detectability of HCCs, no previous study has investigated this, to our knowledge. In this study, the authors evaluated the image quality and the detectability of HCCs in patients with chronic liver disease on DWI with modified MR parameter settings.

Research frontiers
------------------

DWI is an important diagnostic imaging tool for the detection and characterization of liver tumors, including HCC in patients with chronic liver disease. Especially in the case of patients who are contraindicated for a contrast agent, DWI plays an important role for the evaluation of HCCs. Nonetheless, few prior reports have analyzed free-breathing DWI for the liver. The results of the present study may help clarify the clinical utility of free-breathing DWI for the diagnosis of HCC in patients with chronic liver disease.

Innovations and breakthroughs
-----------------------------

In this study, the authors report the clinical utility of FB-DWI with modified MR parameter settings for the improvement of image quality for diagnosing HCC in patients with chronic liver disease. The free-breathing technique is generally avoided in liver DWI because it is hampered by image distortion and/or chemical shift artifacts related to the echo planar imaging technique and to motion and susceptibility artifacts. They evaluated the clinical impacts of previously reported modified MR parameter settings to overcome these issues with FB-DWI. FB-DWI with modified MR parameter settings provided better image quality without reducing the SNR of the normal liver parenchyma and the lesion-to-nonlesion CNR. In addition, the improvement of the image quality of FB-DWI might help increase the detection of HCCs.

Applications
------------

These findings indicate that FB-DWI with modified MR parameter settings is especially useful for patients who are contraindicated for contrast agents and have difficulty holding their breath during the MRI scan. The improvement of image quality helps increase the detection of HCCs without reducing the SNR of the normal liver parenchyma and the lesion-to-nonlesion CNR.

Terminology
-----------

FB-DWI: Diffusion-weighted imaging using free-breathing technique during the scan; RT-DWI: Diffusion-weighted imaging using a navigator-echo-based, real-time respiratory-gating and respiratory-triggering technique during the scan.
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